The present invention relates to a solid extended release pharmaceutical dosage form, comprising a mixture in the form of an extended release matrix formulation, the mixture comprising at least: (1) at least one poly(e-caprolactone), and (2) at least one polyethylene oxide, and (3) at least one active agent.